Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 10, 2009

CTMM to Provide $319M in Funding for Eight R&D Projects in the Netherlands

CTMM to Provide $319M in Funding for Eight R&D Projects in the Netherlands

Eight Dutch R&D projects in the Netherlands to be given $319M

  • The Center for Translational Molecular Medicine (CTMM) reported it will fund eight R&D projects on new techniques for the diagnosis and treatment of major diseases with almost €250 million, or $319 million. The Dutch government will contribute half the funding, with the rest coming from the industry and academia.

    The funding will be allocated to 13 university medical centers and research institutes, 29 SMEs (small- and medium-sized enterprises), and 15 industrial organizations.

    The newly approved projects include those that target cancer as well as cardiovascular, neurodegenerative, and infectious diseases, says the center. New technology platforms such as medical imaging techniques that can be applied across a broad spectrum of these diseases will also be developed.

    The CTMM says it will also continue to invest in centralized infrastructures for company projects to address the demand for advanced genomics, proteomics, metabolomics, and bioinformatics.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »